The hematopoietic stem cell compartment of JAK2V617F-positive myeloproliferative disorders is a reflection of disease heterogeneity

Blood

Volumn 112, Issue 6, 2008, Pages 2429-2438

  James, Chloe ^a,c   Mazurier, Frederic ^a,b   Dupont, Sabrina ^c,d   Chaligne, Ronan ^c,d   Lamrissi Garcia, Isabelle ^a,b   Tulliez, Micheline ^e   Lippert, Eric ^a,b,f   Marion, François Xavier ^a,b,f   Pasquet, Jean Max ^a,b   Etienne, Gabriel ^a,b,g   Delhommeau, François ^c,d,h   Giraudier, Stephane ^c,i   Vainchenker, William ^c,d   De Verneuil, Hubert ^a,b  

^a INSERM   (France)

^b UNIVERSITÉ DE BORDEAUX   (France)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d UNIVERSITÉ PARIS SACLAY   (France)

^e ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^f BORDEAUX UNIVERSITY HOSPITAL   (France)

^g INSTITUT BERGONIÉ   (France)

^h HÔPITAL SAINT ANTOINE   (France)

ⁱ HENRI MONDOR HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; JANUS KINASE 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL PROLIFERATION; CELL RENEWAL; CLINICAL ARTICLE; GENE FREQUENCY; GENE MUTATION; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; MYELOFIBROSIS; MYELOPROLIFERATIVE DISORDER; NONHUMAN; NONOBESE DIABETIC MOUSE; POLYCYTHEMIA VERA; PRIORITY JOURNAL; SCID MOUSE; WILD TYPE; XENOTRANSPLANTATION; ANIMAL; GENETICS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; MISSENSE MUTATION; MOUSE MUTANT; PATHOLOGY; PHENOTYPE; XENOGRAFT;

ANIMALS; CELL PROLIFERATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HUMANS; JANUS KINASE 2; MICE; MICE, SCID; MUTATION, MISSENSE; MYELOFIBROSIS; MYELOPROLIFERATIVE DISORDERS; PHENOTYPE; POLYCYTHEMIA VERA; TRANSPLANTATION, HETEROLOGOUS;

EID: 54049110222     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-02-137877     Document Type: Article

References (31)

1. Adamson JW, Fialkow PJ, Murphy S, Prchal JF, Steinmann L. Polycythemia vera: stem-cell and probable clonal origin of the disease. N Engl J Med. 1976;295:913-916.
2. Takahashi N, Miura I, Saitoh K, MiuraAB. Lineage involvement of stem cells bearing the Philadelphia chromosome in chronic myeloid leukemia in the chronic phase as shown by a combination of fluorescence-activated cell sorting and fluorescence in situ hybridization. Blood. 1998;92:4758-4763.
3. Xu M, Bruno E, Chao J, et al. The constitutive mobilization of bone marrow-repopulating cells into the peripheral blood in idiopathic myelofibrosis. Blood. 2005;105:1699-1705.
4. James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005; 434:1144-1148.
5. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005:365: 1054-1061.
6. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352:1779-1790.
7. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7:387-397.
8. Delhommeau F, Dupont S, Tonetti C, et al. Evidence that the JAK2 G1849T(V617F) mutation occurs in a lymphomyeloid progenitor in polycythemia vera and idiopathic myelofibrosis. Blood. 2007;109:71-77.
9. Jamieson CH, Gotlib J, Durocher JA, et al. The JAK2V617F mutation occurs in hematopoietic stem cells in polycythemia vera and predisposes toward erythroid differentiation. Proc Natl Acad Sci U S A. 2006;103:6224-6229.
10. Dupont S, Masse A, James C, et al. The JAK2 617V>F mutation triggers erythropoietin hypersensitivity and terminal erythroid amplification in primary cells from patients with polycythemia vera. Blood. 2007;110:1013-1021.
11. Ishii T, Zhao Y, Sozer S, etal. Behavior of CD34+ cells isolated from patients with polycythemia vera in NOD/SCID mice. Exp Hematol. 2007;35: 1633-1640.
12. Tanaka T, Tsudo M, Karasuyama H, et al. A novel monoclonal antibody against murine IL-2 receptor beta-chain: characterization of receptor expression in normal lymphoid cells and EL-4 cells. J Immunol. 1991;147:2222-2228.
13. Robert-Richard E, Ged C, Ortet J, et al. Human cell engraftment after busulfan or irradiation conditioning of NOD/SCID mice. Haematologica. 2006;91:1384.
14. Lippert E, Boissinot M, Kralovics R, et al. The JAK2-V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia vera. Blood. 2006; 108: 1865-1867.
15. Abkowitz JL, Chen J. Studies of c-MpI function distinguish the replication of hematopoietic stem cells from the expansion of differentiating clones. Blood. 2007;109:5186-5190.
16. Sirard C, Lapidot T, Vormoor J, et al. Normal and leukemic SCID-repopulating cells (SRC) coexist in the bone marrow and peripheral blood from CML patients in chronic phase, whereas leukemic SRC are detected in blast crisis. Blood. 1996;87: 1539-1548.
17. Lewis ID, McDiarmid LA, Samels LM, To LB, Hughes TP. Establishment of a reproducible model of chronic-phase chronic myeloid leukemia in NOD/SCID mice using blood-derived mononuclear or CD34+ cells. Blood. 1998;91:630-640.
18. Petzer AL, Eaves CJ, Barnett MJ, Eaves AC. Selective expansion of primitive normal hematopoietic cells in cytokine-supplemented cultures of purified cells from patients with chronic myeloid leukemia. Blood. 1997;90:64-69.
19. Holyoake T, Jiang X, Eaves C, Eaves A. Isolation of a highly quiescent subpopulation of primitive leukemic cells in chronic myeloid leukemia. Blood. 1999;94:2056-2064.
20. Huntly BJ, Gilliland DG. Cancer biology: summing up cancer stem cells. Nature. 2005;435:1169-1170.
21. Eisterer W, Jiang X, Christ O, et al. Different subsets of primary chronic myeloid leukemia stem cells engraft immunodeficient mice and produce a model of the human disease. Leukemia. 2005;19: 435-441.
22. Nussenzveig RH, Swierczek SI, Jelinek J, et al. Polycythemia vera is not initiated by JAK2V617F mutation. Exp Hematol. 2007;35:32-38.
23. Gaikwad A, Nussenzveig R, Liu E, Gottshalk S, Chang K, Prchal JT. In vitro expansion of erythroid progenitors from polycythemia vera patients leads to decrease in JAK2V617F allele. Exp Hematol. 2007:35:587-595.
24. Lin H, Monaco G, Sun T, et al. Bcr-Abl-mediated suppression of normal hematopoiesis in leukemia. Oncogene. 2005;24:3246-3256.
25. Martyre MC, Romquin N, Le Bousse-Kerdiles MC, et al. Transforming growth factor-beta and megakaryocytes in the pathogenesis of idiopathic myelofibrosis. Br J Haematol. 1994;88:9-16.
26. Chagraoui H, Komura E, Tulliez M, Giraudier S, Vainchenker W, Wendling F. Prominent role of TGF-beta 1 in thrombopoietin-induced myelofibrosis in mice. Blood. 2002;100:3495-3503.
27. Fortunel NO, Hatzfeld A, Hatzfeld JA. Transforming growth factor-beta: pleiotropic role in the regulation of hematopoiesis. Blood. 2000;96:2022-2036.
28. Le Bousse-Kerdiles MC, Chevillard S, Charpentier A, et al. Differential expression of transforming growth factor-beta, basic fibroblast growth factor, and their receptors in CD34+ hematopoietic progenitor cells from patients with myelofibrosis and myeloid metaplasia. Blood. 1996:88:4534-4546.
29. Villeval JL, James C, Pisani DF, Casadevall N, Vainchenker W. New insights into the pathogenesis of JAK2V617F-positive myeloproliferative disorders and consequences for the management of patients. Semin Thromb Hemost. 2006;32:341-351.
30. Lu X, Levine R, Tong W, et al. Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation. Proc Natl Acad Sci U S A. 2005;102:18962-18967.
31. Copland M, Hamilton A, Elrick LJ, et al. Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary GML but does not eliminate the quiescent fraction. Blood. 2006;107: 4532-4539.